Info@ThinkPinkRocks.com

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

More:
IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Share

Leave a Reply